Loading organizations...
Biointron is a contract research organization based in Shanghai, China, that specializes in high-throughput recombinant protein expression and custom antibody discovery services for the biopharmaceutical industry. Operating with a workforce of 201 to 500 employees, the company delivers over 100,000 recombinant antibodies annually from gene sequence to purified product. The organization provides its fee-for-service screening, humanization, and affinity maturation solutions to a global client base of more than 1,500 biotechnology and pharmaceutical companies. Following an undisclosed Series C financing round in late 2022, the enterprise secured venture capital backing from institutional investors including Qiming Venture Partners, Sequoia Capital China, and GL Ventures. This funding facilitated the opening of a new laboratory and office facility in New Jersey to scale global production. Biointron was founded in 2012 and is currently led by Chief Executive Officer Zha Changchun.
Biointron has raised $72.5M across 1 funding round.
Biointron has raised $72.5M in total across 1 funding round.
Biointron has raised $72.5M across 1 funding round. Most recently, it raised $72.5M Series B in August 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 31, 2022 | $72.5M Series B | — | CS Capital, Gaorong Capital, October Capital | Announced |
Biointron has raised $72.5M in total across 1 funding round.
Biointron's investors include CS Capital, Gaorong Capital, October Capital.
